JP2015514096A5 - - Google Patents

Download PDF

Info

Publication number
JP2015514096A5
JP2015514096A5 JP2015503646A JP2015503646A JP2015514096A5 JP 2015514096 A5 JP2015514096 A5 JP 2015514096A5 JP 2015503646 A JP2015503646 A JP 2015503646A JP 2015503646 A JP2015503646 A JP 2015503646A JP 2015514096 A5 JP2015514096 A5 JP 2015514096A5
Authority
JP
Japan
Prior art keywords
composition
body weight
weeks
neuregulin
effective amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015503646A
Other languages
English (en)
Japanese (ja)
Other versions
JP6420233B2 (ja
JP2015514096A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2013/034634 external-priority patent/WO2013149163A1/en
Publication of JP2015514096A publication Critical patent/JP2015514096A/ja
Publication of JP2015514096A5 publication Critical patent/JP2015514096A5/ja
Application granted granted Critical
Publication of JP6420233B2 publication Critical patent/JP6420233B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015503646A 2012-03-30 2013-03-29 末梢神経損傷を処置するためのニューレグリンの使用 Expired - Fee Related JP6420233B2 (ja)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US201261618381P 2012-03-30 2012-03-30
US61/618,381 2012-03-30
US201261674060P 2012-07-20 2012-07-20
US61/674,060 2012-07-20
US201261693585P 2012-08-27 2012-08-27
US201261693589P 2012-08-27 2012-08-27
US61/693,589 2012-08-27
US61/693,585 2012-08-27
US201361785419P 2013-03-14 2013-03-14
US61/785,419 2013-03-14
PCT/US2013/034634 WO2013149163A1 (en) 2012-03-30 2013-03-29 Use of neuregulin to treat peripheral nerve injury

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017076415A Division JP2017149746A (ja) 2012-03-30 2017-04-07 末梢神経損傷を処置するためのニューレグリンの使用

Publications (3)

Publication Number Publication Date
JP2015514096A JP2015514096A (ja) 2015-05-18
JP2015514096A5 true JP2015514096A5 (enExample) 2015-08-06
JP6420233B2 JP6420233B2 (ja) 2018-11-07

Family

ID=48128617

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2015503646A Expired - Fee Related JP6420233B2 (ja) 2012-03-30 2013-03-29 末梢神経損傷を処置するためのニューレグリンの使用
JP2017076415A Pending JP2017149746A (ja) 2012-03-30 2017-04-07 末梢神経損傷を処置するためのニューレグリンの使用
JP2019070976A Pending JP2019131582A (ja) 2012-03-30 2019-04-03 末梢神経損傷を処置するためのニューレグリンの使用
JP2021004728A Active JP7108724B2 (ja) 2012-03-30 2021-01-15 末梢神経損傷を処置するためのニューレグリンの使用

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2017076415A Pending JP2017149746A (ja) 2012-03-30 2017-04-07 末梢神経損傷を処置するためのニューレグリンの使用
JP2019070976A Pending JP2019131582A (ja) 2012-03-30 2019-04-03 末梢神経損傷を処置するためのニューレグリンの使用
JP2021004728A Active JP7108724B2 (ja) 2012-03-30 2021-01-15 末梢神経損傷を処置するためのニューレグリンの使用

Country Status (15)

Country Link
US (3) US20150094263A1 (enExample)
EP (3) EP2830645B1 (enExample)
JP (4) JP6420233B2 (enExample)
CN (2) CN104321072A (enExample)
AU (4) AU2013237896B2 (enExample)
BR (1) BR112014024308B1 (enExample)
CA (1) CA2869070A1 (enExample)
DK (2) DK3278811T3 (enExample)
ES (2) ES2647917T3 (enExample)
IL (3) IL288785B2 (enExample)
MX (1) MX354598B (enExample)
NZ (1) NZ700546A (enExample)
PL (2) PL3278811T3 (enExample)
PT (2) PT2830645T (enExample)
WO (1) WO2013149163A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3338791T3 (da) 2008-07-17 2019-12-16 Acorda Therapeutics Inc Terapeutisk dosering af en neuregulin i behandling eller profylaxis af hjertesvigt
PL3235504T3 (pl) 2009-10-14 2020-03-31 Acorda Therapeutics, Inc. Zastosowanie neureguliny do leczenia uszkodzenia nerwu obwodowego
ITUB20155471A1 (it) * 2015-11-11 2017-05-11 Univ Degli Studi Di Torino Coniugato della neuregulina 1 per il trattamento delle lesioni dei nervi periferici
IL294038A (en) * 2015-12-04 2022-08-01 Univ Iowa Res Found Device, systems and methods for prediction, screening and monitoring of encephalopathy / delirium
CA3082878C (en) 2017-11-17 2024-02-20 The Research Foundation for State University of New York A method for treating damaged peripheral nerves using x-ray microbeam irradiation
CN110946991A (zh) * 2018-09-27 2020-04-03 广州中医药大学(广州中医药研究院) 神经调节蛋白1的应用
CN114929099B (zh) * 2019-08-01 2025-08-15 马克·埃文斯 用于在分娩期间和分娩之前降低人类胎儿神经损伤风险及鉴定神经损伤存在的方法和设备
CN116116737B (zh) * 2023-04-14 2023-06-30 新华手术器械有限公司 止血钳毛坯自动上料装置及使用方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US888A (en) 1838-08-20 perkins
US7037A (en) 1850-01-22 Grid-ikon slide-valve
US5716930A (en) 1991-04-10 1998-02-10 Ludwig Institute For Cancer Research Glial growth factors
US5530109A (en) 1991-04-10 1996-06-25 Ludwig Institute For Cancer Research DNA encoding glial mitogenic factors
US6087323A (en) * 1992-04-03 2000-07-11 Cambridge Neuroscience, Inc. Use of neuregulins as modulators of cellular communication
US7037888B1 (en) 1992-04-03 2006-05-02 Acorda Therapeutics, Inc. Methods for treating muscle diseases and disorders
EP1028735A4 (en) * 1997-10-14 2003-08-06 Cenes Pharmaceuticals Inc THERAPEUTIC METHOD COMPRISING THE USE OF NEUREGULIN
CA2409996C (en) * 2000-05-23 2016-03-01 Cenes Pharmaceuticals, Inc. Nrg-2 nucleic acid molecules, polypeptides, and diagnostic and therapeutic methods
WO2009046453A2 (en) * 2007-10-05 2009-04-09 New England Medical Center (Nemc) Use of neuregulin-1 in reducing brain damage
CN104645315A (zh) * 2008-02-29 2015-05-27 阿索尔达治疗公司 达到所需胶质生长因子2血浆水平的方法
DK3338791T3 (da) * 2008-07-17 2019-12-16 Acorda Therapeutics Inc Terapeutisk dosering af en neuregulin i behandling eller profylaxis af hjertesvigt
KR101237927B1 (ko) * 2009-05-07 2013-03-04 (주)문엔제이 신경손상 및 신경질환 예방 또는 치료용 약학조성물
PL3235504T3 (pl) * 2009-10-14 2020-03-31 Acorda Therapeutics, Inc. Zastosowanie neureguliny do leczenia uszkodzenia nerwu obwodowego
CA2845198A1 (en) * 2010-08-13 2012-02-16 Georgetown University Ggf2 and methods of use

Similar Documents

Publication Publication Date Title
JP2015514096A5 (enExample)
Bansal et al. The occurrence and pattern of ameloblastoma in children and adolescents: an Indian institutional study of 41 years and review of the literature
JP2017039771A5 (enExample)
JP2021059605A5 (enExample)
JP2015500225A5 (enExample)
EA200900203A1 (ru) Избирательные модуляторы рецептора андрогенов, их аналоги, производные и применение
JP2013542190A5 (enExample)
HK1202776A1 (en) Use of laquinimod for treating crohn's disease patients who failed first-line anti-tnf therapy
JP2016509601A5 (enExample)
JP2017522288A5 (enExample)
RU2013127420A (ru) Способы уменьшения психогенного или компульсивного переедания
MX395613B (es) COMPOSICIONES DE ZINC-y-PGA Y MÉTODOS PARA TRATAR EL CANCER.
BR112022010806A2 (pt) Métodos para tratar câncer de mama, para inibir o crescimento tumoral e para prevenir ou retardar o desenvolvimento de resistência de um câncer de mama
NZ754328A (en) Marker for acid sphingomyelinase disorders and uses thereof
RU2020120156A (ru) Лечение приливов и потери костной ткани, вызванных андрогенной депривационной терапией с применением цис-кломифена
WO2014100679A8 (en) Stimulation and enhancement of regeneration of tissues
MX367580B (es) El uso de lapatinib o una sal o composición farmacéuticamente aceptable del mismo para el tratamiento del cáncer.
RU2018114457A (ru) Лечение syd985 пациентов с t-dm1 рефрактерным раком
Rodda et al. Quality of life outcomes: ASCENDE-RT a multicenter randomized trial of radiation therapy for prostate cancer
Tsutsumi et al. Colonoscopy using an abdominal bandage
SG10201708886RA (en) α-PGA-ZINC COMPOSITIONS AND METHODS FOR TREATING CANCER
O’kane et al. Vismodegib in the treatment of advanced BCC
Joshua et al. Desmoplastic fibroma of the mandible associated with pathological fracture in a pediatric patient
Sahu et al. Parietal wall endometriosis: a rare case report
Terent’eva Ultrasound for breast condition monitoring in females using levonorgestrel-containing intrauterine systems for 5 years